XM does not provide services to residents of the United States of America.
U
U

UCB

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

EMA Starts Review Of Drugs Containing Finasteride & Dutasteride After Suicidal Ideation Concerns

CORRECTED-BRIEF-EMA Starts Review Of Drugs Containing Finasteride & Dutasteride After Suicidal Ideation Concerns Corrects source of brief to European Medicines Agency, not Merck & Co Oct 4 (Reuters) - European Medicines Agency (EMA): EMA: HAS STARTED A REVIEW OF MEDICINES CONTAINING FINASTERIDE AND DUTASTERIDE FOLLOWING CONCERNS REGARDING SUICIDAL
U

UCB Announces A Study Evaluating Bimzelx Versus Skyrizi In Psoriatic Arthritis

BRIEF-UCB Announces A Study Evaluating Bimzelx Versus Skyrizi In Psoriatic Arthritis Sept 30 (Reuters) - Ucb SA UCB.BR : ANNOUNCES A HEAD-TO-HEAD STUDY EVALUATING BIMZELX[®]▼(BIMEKIZUMAB) VERSUS SKYRIZI® (RISANKIZUMAB) IN ACTIVE PSORIATIC ARTHRITIS STUDY UNDERSCORES UCB'S BELIEF IN BIMEKIZUMAB WITH TOP-LINE RESULTS EXPECTED IN 2026 Source text:
U

UCB Announces Late-Breaking 2 Year Data For Bimekizumab In HS

BRIEF-UCB Announces Late-Breaking 2 Year Data For Bimekizumab In HS Sept 27 (Reuters) - Ucb SA UCB.BR : ANNOUNCES LATE-BREAKING TWO-YEAR DATA FOR BIMZELX(BIMEKIZUMAB) IN MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA AT EADV 2024 CLINICALLY MEANINGFUL IMPROVEMENTS OBSERVED WITH BIMEKIZUMAB OVER ONE YEAR OF TREATMENT WERE MAINTAINED UP TO TWO YEARS (WE
U

Biogen rises after lupus drug meets main goal of late-stage study

BUZZ-Biogen rises after lupus drug meets main goal of late-stage study ** Shares of drugmaker Biogen BIIB.O rise 2.1% to $200 premarket ** Co and partner UCB UCB.BR say their experimental lupus treatment met the main goal of a late-stage trial ** Cos say the drug, dapirolizumab pegol, when given along with other standard of care treatments, showed
B
U

UCB Announces Positive Results From Phase 3 Study Of Dapirolizumab Pegol

BRIEF-UCB Announces Positive Results From Phase 3 Study Of Dapirolizumab Pegol Sept 24 (Reuters) - UCB UCB.BR : UCB AND BIOGEN ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY OF DAPIROLIZUMAB PEGOL IN SYSTEMIC LUPUS ERYTHEMATOSUS ARE INITIATING SECOND PHASE 3 STUDY IN 2024 PARTICIPANTS FROM PHOENYCS GO STUDY WILL CONTINUE TO BE FOLLOWED IN A L
B
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.